Viking Therapeutics (VKTX) Stock Pops on Plans to Start Late-Stage Weight Loss Drug Trials

The results from the Phase 2 trial showed much promise with it meeting its primary and all secondary endpoints. That includes significant weight loss for those taking VK2735 when compared to patients taking a placebo. To go along with this, the company reported adjusted EPS of -20 cents in the second quarter of 2024. That's worth highlighting as it beats out Wall Street's estimate of -24 cents for the quarter. Viking Therapeutics says that it's ready to progress subcutaneous VK2735 into a Phase 3 clinical t ...